Perioperative remimazolam administration to prevent delirium and neurocognitive disorders after surgery: a systematic review and meta-analysis.

ABSTRACT:

Aims

Remimazolam is a novel, ultra-short-acting intravenous benzodiazepine. Its efficacy in reducing the occurrence of postoperative delirium (POD) and neurocognitive disorders remains unclear. Therefore, we conducted a meta-analysis to evaluate the long-term effects of remimazolam on POD and neurocognitive disorders.

Methods and results

We searched PubMed, Embase, and Web of Science, covering the period from their inception to September 30, 2024. Randomized controlled trials (RCTs) and cohort studies comparing remimazolam with propofol or other sedative medical therapy were included. The primary outcome was the incidence of POD, while secondary outcomes included hypotension, hypoxia, bradycardia, agitation, and vomiting. A total of 11 studies involving 2188 patients were in

SUBMITTER: Xi D 

PROVIDER: S-EPMC12486766 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature